Chiesi's carbon minimal inhalers reach innovation milestone as phase III trials now underway
Chiesi, the international research-focused biopharmaceutical and healthcare group, has announced that its phase III clinical safety trial for the development of an innovative carbon minimal inhaler platform is underway.1 The carbon minimal inhaler will replace the current hydrofluorocarbon propellant (HFC 134a) ...
Source: pharmiweb.com